Products
Our diverse technology portfolio enables us to develop products that enhance the lives of patients throughout the world.
We have leveraged our proprietary drug delivery technologies to develop a diverse product portfolio in a range of therapeutic areas. Our current product portfolio includes our own proprietary pharmaceutical products, co-development programs, and products that are enhanced versions of existing drugs available for licensing.
Whether developed in-house or in conjunction with a valued client, our pharmaceutical products are a testament to the innovation and broad application of our technologies. Currently, more than 40 products using our technologies are commercialized worldwide.
Eurand is Changing
Increasingly, we are commiting resources to develop our own proprietary product pipeline. We are using our technology platforms to create new products, improve the efficacy and safety of others and create dosage forms that improve patient convenience and compliance.
In 2005, we received approval in the United States for an ANDA version of a marketed drug. In early 2007, we completed two phase III trials for a life-saving product that is used in the treatment of Exocrine Pancreatic Insufficiency, a disease often associated with cystic fibrosis and chronic pancreatitis, among others.
Other product candidates are progressing through various stages of formulation and clinical development; additional information can be found under Development Pipeline.